


Ifw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of Samuel Jotham REICH et al.

Application No.: 10/699,557

Filed: October 31, 2003

For: COMPOSITIONS AND METHODS FOR siRNA
INHIBITION OF HIF-1 alphaGroup Art Unit:
1642Examiner:
Not Yet AssignedCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying substitute Form PTO-1449.

The Examiner is respectfully requested to review the items listed on the attached substitute Form PTO-1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form PTO-1449, and return one copy to the undersigned. Copies of the U.S. patents and published patent applications cited on the substitute Form PTO 1449 need not be submitted pursuant to 1276 OG 55 (August 5, 2003).

This Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application, but before the mailing date of the first Office Action on the merits. Accordingly, no certification, petition, or fee is required. However, should a fee be due, please charge the fee or credit any overcharge to Deposit Account No. 50-0573.

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. box 1450, Alexandria, VA 223313-1450 on the date shown below.	
BY	<u>Karen Spina</u>
DATE: 10/6/04	Karen Spina

This Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

Respectfully submitted,

SAMUEL JOTHAM REICH, *et al.*

Date: October 5, 2004

By: 

GEORGE A. FRANK

Registration No. 27,636

DRINKER BIDDLE & REATH LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

TEL: (215) 988-2822

FAX: (215) 988-2757

Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 43826-0002 US1	APPLICATION NUMBER 10/699,557
	FIRST NAMED INVENTOR REICH et al.	
	FILING DATE 10/31/2003	ART UNIT 1642



U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number-Kind Code (if known)	PUBLICATION DATE (MM/DD/YYYY)	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A	2002/0086356 A1	07/04/2002	TUSCHL et al.	
	B	2002/0132788 A1	09/19/2002	LEWIS et al.	
	C	2002/0162126 A1	10/31/2002	BEACH et al.	
	D	2002/0173478 A1	11/21/2002	GEWIRTZ	
	E	6,506,559	11/14/2003	FIRE al.	
	F	6,177,401	01/23/2001	ULLRICH et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	FOREIGN PATENT DOCUMENT Country Code-Number-Kind Code (if known)	PUBLICATION DATE (MM/DD/YYYY)	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	G	CA 2359180	08/03/2000	KREUTZER et al.		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	H	Bennett et al., <i>Hum Gene Ther</i> 10:1763-1769 (abstract) (Sept. 1996)	
	I	Elbashir et al., <i>Nature</i> , 411:494-498 (24 May 2001)	
	J	Elbashir et al., <i>Genes & Development</i> 15:188-200 (2001)	
	K	Erickson, D., "RNAi Revs Up", <i>Start-Up</i> (A#2002900168) pp. 1-12 (Oct. 2002)	
	L	Fire et al., <i>Nature</i> , 391:806-811 (19 Feb. 1998)	
EXAMINER SIGNATURE		DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 43826-0002 US1	APPLICATION NUMBER 10/699,557
	FIRST NAMED INVENTOR REICH et al.	
	FILING DATE 10/31/2003	ART UNIT 1642

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	M	Hoeg et al., "In vitro and in vivo Efficacy of a HIF-1alpha-antisense oligonucleotide containing locked nucleic acids", <i>ECJ Supplements</i> , pp. S212-S213 (September 2003) (<i>abstract only</i>)	
	N	Holash et al., <i>PNAS</i> , 99(17) 11393-11398 (Aug. 20, 2002)	
	O	Kang et al., "An Antisense Oligonucleotide that Inhibits the Expression of Hypoxia-Inducible Factor-1alpha Alters Hypoxia-Induced Changes in Proliferation and viability of Human Cardiac Fibroblasts", p. II, 57 (<i>abstract only</i>)	
	P	Kim et al., <i>PNAS</i> , 99(17):11399-11404. (Aug. 20, 2002)	
	Q	Novina et al., <i>Nature Medicine</i> , 8(7):81-686 (July 2002)	
	R	Sun et al., "Gene Transfer of Antisense Hypoxia Inducible Factor-1 alpha Enhances the therapeutic Efficacy of Cancer Immunotherapy", <i>Gene Therapy</i> 8:638-645 (2001)	
	S	Tischer et al., <i>J. Biol Chem</i> 266:11947-11954 (abstract) (June 25, 1991)	
	T	Tuschl, T., The siRNA user guide (revised October 11, 2002), Accessed from http://www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html . on 11/1/2002.	
	U	Tuschl, T., <i>Nat. Biotech</i> 20: 446-448 (May 2002)	
	V	Van Brunt, J., <i>Signals Magazine</i> : "Buzz – Shoot the Messenger" 08/22/2002, Accessed from http://www.signalsmag.com/signalsmag..../3DF5AEF6049CC81C99256C1D0055BAA on 10/28/2002.	
	W	Wu et al., <i>Mol Cell Biol</i> , Vol. 22:22: 7758-7768 (abstract) (Nov. 2002)	
	X	Xia et al., <i>Nature Biotechnology</i> , Vol. 20:1006-1010 (Oct. 2002)	
EXAMINER SIGNATURE		DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.